Reversible Symptomatic Biliary Obstruction Associated with Ceftriaxone Pseudolithiasis

Jonathan Zinberg; Richard Chernaik; Eugene Coman; Ruth Rosenblatt; Lawrence J. Brandt

doi:10.1111/j.1572-0241.1991.tb07265.x

Reversible Symptomatic Biliary Obstruction Associated with Ceftriaxone Pseudolithiasis

Jonathan Zinberg, Richard Chernaik, Eugene Coman, Ruth Rosenblatt, Lawrence J. Brandt

Medicine

Research output: Contribution to journal › Article

49 Scopus citations

Abstract

Ceftriaxone, a third‐generation cephalosporin, has been associated with the development of sludge or stones in the gallbladders of some patients treated with this medication. Such precipitates, which are usually reversible upon discontinuation of the drug, sometimes cause symptoms, have simulated acute cholecystitis, and have even led to cholecystectomy in some cases. We report the first known instance of biliary obstruction and secondary pancreatitis in association with reversible ceftriaxone‐induced pseudolithiasis.

Original language	English (US)
Pages (from-to)	1251-1254
Number of pages	4
Journal	The American Journal of Gastroenterology
Volume	86
Issue number	9
DOIs	https://doi.org/10.1111/j.1572-0241.1991.tb07265.x
State	Published - Sep 1991

Fingerprint

ASJC Scopus subject areas

Hepatology
Gastroenterology

Cite this

Zinberg, J., Chernaik, R., Coman, E., Rosenblatt, R., & Brandt, L. J. (1991). Reversible Symptomatic Biliary Obstruction Associated with Ceftriaxone Pseudolithiasis. The American Journal of Gastroenterology, 86(9), 1251-1254. https://doi.org/10.1111/j.1572-0241.1991.tb07265.x

@article{de1406d39c3b40649f6a78502661f417,

title = "Reversible Symptomatic Biliary Obstruction Associated with Ceftriaxone Pseudolithiasis",

abstract = "Ceftriaxone, a third‐generation cephalosporin, has been associated with the development of sludge or stones in the gallbladders of some patients treated with this medication. Such precipitates, which are usually reversible upon discontinuation of the drug, sometimes cause symptoms, have simulated acute cholecystitis, and have even led to cholecystectomy in some cases. We report the first known instance of biliary obstruction and secondary pancreatitis in association with reversible ceftriaxone‐induced pseudolithiasis.",

author = "Jonathan Zinberg and Richard Chernaik and Eugene Coman and Ruth Rosenblatt and Brandt, {Lawrence J.}",

year = "1991",

month = sep

doi = "10.1111/j.1572-0241.1991.tb07265.x",

language = "English (US)",

volume = "86",

pages = "1251--1254",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Reversible Symptomatic Biliary Obstruction Associated with Ceftriaxone Pseudolithiasis

AU - Zinberg, Jonathan

AU - Chernaik, Richard

AU - Coman, Eugene

AU - Rosenblatt, Ruth

AU - Brandt, Lawrence J.

PY - 1991/9

Y1 - 1991/9

N2 - Ceftriaxone, a third‐generation cephalosporin, has been associated with the development of sludge or stones in the gallbladders of some patients treated with this medication. Such precipitates, which are usually reversible upon discontinuation of the drug, sometimes cause symptoms, have simulated acute cholecystitis, and have even led to cholecystectomy in some cases. We report the first known instance of biliary obstruction and secondary pancreatitis in association with reversible ceftriaxone‐induced pseudolithiasis.

AB - Ceftriaxone, a third‐generation cephalosporin, has been associated with the development of sludge or stones in the gallbladders of some patients treated with this medication. Such precipitates, which are usually reversible upon discontinuation of the drug, sometimes cause symptoms, have simulated acute cholecystitis, and have even led to cholecystectomy in some cases. We report the first known instance of biliary obstruction and secondary pancreatitis in association with reversible ceftriaxone‐induced pseudolithiasis.

UR - http://www.scopus.com/inward/record.url?scp=0026009929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026009929&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.1991.tb07265.x

DO - 10.1111/j.1572-0241.1991.tb07265.x

M3 - Article

C2 - 1882806

AN - SCOPUS:0026009929

VL - 86

SP - 1251

EP - 1254

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 9

ER -

Access to Document

10.1111/j.1572-0241.1991.tb07265.x